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Activation of PKR (double-stranded-RNA-dependent protein
kinase) by DNA plasmids decreases translation, and limits the
amount of recombinant protein produced by transiently transfec-
ted HEK (human embryonic kidney)-293 cells. Co-expression
with Ebola virus VP35 (virus protein 35), which blocked
plasmid activation of PKR, substantially increased production of
recombinant TPL-2 (tumour progression locus 2)–ABIN-2 [A20-
binding inhibitor of NF-κB (nuclear factor κB) 2]–NF-κB1 p105
complex. VP35 also increased expression of other co-transfected
proteins, suggesting that VP35 could be employed generally to
boost recombinant protein production by HEK-293 cells.
Key words: A20-binding inhibitor of nuclear factor κB 2
(ABIN-2), cancer Osaka thyroid (COT), nuclear factor κB 1 (NF-
κB1), double-stranded-RNA-dependent protein kinase (PKR),
tumour progression locus 2 (TPL-2), virus protein 35 (VP35).
INTRODUCTION
TPL-2 (tumour progression locus 2) [also known as MAP3K8
(mitogen-activated protein kinase kinase kinase 8) and
COT (cancer Osaka thyroid)] mediates activation of ERK
(extracellular-signal-regulated kinase) 1 and 2 MAPKs (mitogen-
activated protein kinases) by Toll-like receptors and the receptors
for TNF (tumour necrosis factor) and interleukin 1β in
macrophages [1]. Lipopolysaccharide induction of TNF in vivo
and in cultured macrophages is dependent on TPL-2 expression
[2]. Consequently, TPL-2 has attracted considerable attention as a
potential target for the development of small-molecule inhibitors
to treat TNF-driven inflammatory diseases, including rheumatoid
arthritis, Crohn’s disease and psoriasis [3,4].
In unstimulated cells, TPL-2 is stoichiometrically associated
with NF-κB (nuclear factor κB) 1 p105 and the ubiquitin-binding
protein ABIN-2 (A20-binding inhibitor of NF-κB2), which are
both required to maintain TPL-2 protein stability [5–9]. Direct
binding of NF-κB1 p105 to the TPL-2 kinase domain also
negatively regulates TPL-2 MKK (MAPK kinase) 1/2 activity
by blocking access of MKK1/2 to its active site [5,8]. TPL-2
phosphorylation of MKK1/2 and activation of ERK1/2 MAPK
signalling consequently requires TPL-2 release from NF-κB1
p105, which is triggered by IKK [IκB (inhibitor of NF-κB)
kinase]-induced proteolysis of NF-κB1 p105 by the proteasome
following agonist stimulation [10,11].
We have recently made an unexpected discovery about how
TPL-2 regulates TNF production by macrophages. Analyses
of Nfkb1SSAA/SSAA macrophages, in which the IKK target serine
residues on NF-κB1 p105 are mutated to alanine, revealed
that TPL-2 regulates TNF production independently of IKK-
induced NF-κB1 p105 proteolysis and ERK1/2 activation, while
still associated with NF-κB1 p105 and ABIN-2 [12]. These
data indicate that the TPL-2–ABIN-2–NF-κB1 p105 complex
phosphorylates substrates other than MKK1/2 to stimulate TNF
production, and that small-molecule inhibitors should target this
complex to block TNF production. However, no method is
currently available to express and purify the catalytically active
TPL-2 signalling complex.
In the present study, a novel methodology to produce milligram
quantities of highly pure catalytically active recombinant TPL-
2–ABIN-2–NF-κB1 p105 complex in transiently transfected
mammalian HEK (human embryonic kidney)-293 cells was
developed, which is based on co-expression of Ebola virus VP35
(virus protein 35) to antagonize transfection-induced inhibition
of translation. VP35 co-transfection increased protein expres-
sion of recombinant TPL-2 complex more than 10-fold.
Importantly, we found evidence to suggest that this approach
could be readily adapted to boost the expression of any
recombinant cytosolic or membrane-bound protein.
EXPERIMENTAL
Cell culture
Adherent HEK-293 cells (QBI293A cells, Quantum Biotechno-
logies) were maintained as described previously [13]. Cells were
adapted to growth in suspension using Pro293s-CDM medium
(Lonza), supplemented with 1.5% fetal bovine serum, 2 mM L-
glutamine, 50 units/ml penicillin and 50 units/ml streptomycin,
Abbreviations used: ABIN-2, A20-binding inhibitor of nuclear factor κB 2; BMDM, bone-marrow-derived macrophage; DM, decyl β-D-maltopyranoside;
DTT, dithiothreitol; ERK, extracellular-signal-regulated kinase; GST, glutathione transferase; HA, haemagglutinin; HEK, human embryonic kidney; Hsp,
heat-shock protein; IκB, inhibitor of NF-κB; IKK, IκB kinase; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; MKK, MAPK kinase;
NF-κB, nuclear factor κB; PKR, double-stranded RNA-dependent protein kinase; TBK1, TANK [TRAF (tumour-necrosis-factor-receptor-associated factor)-
associated NF-κB activator]-binding kinase 1; TCEP, tris-(2-carboxyethyl)phosphine; TNF, tumour necrosis factor; TPL-2, tumour progression locus 2;
VP35, virus protein 35.
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and were cultured to between 1.5 × 106 and 4.0 × 106 cells/ml in
1-litre spinner flasks (Techne). BMDMs (bone-marrow-derived
macrophages) were generated from C57BL/6 mice as described
previously [10]. All procedures described in the present study
involving animals were done in accordance with U.K. Home
Office regulations.
Expression plasmids and antibodies
Expression plasmids encoding His6-tagged TPL-2 and TPL-2D270A
(NCBI RefSeq NP_001231063.1), FLAG-tagged human TPL-2
and TPL-230–397, and C-terminally StrepII-tagged ABIN-2 (NCBI
RefSeq NP_077285.3) were generated by PCR amplification
and subcloning into the pCDNA3 vector (Life Technologies).
The pCDNA3-3xHA-IKK-2 expression construct was generated
by subcloning from pRc-β-actin-3xHA-IKK-2 (provided by
Professor Michael Karin, University of California San Diego, San
Diego, CA, U.S.A.). Plasmids encoding Bcl-2 (pMT2), CD40
(pSRalpha), Lck (pCDNA3), HA (haemagglutinin)-tagged NF-
κB1 p105 (pCDNA3), Myc–His–TBK1 {TANK [TRAF (TNF-
receptor-associated factor)-associated NF-κB activator]-binding
kinase 1} (pCDNA3), and HA–VP35 of the Ebola virus species
Zaire ebolavirus (Mayinga isolate) [pCDNA3.1/myc-His( − )A]
have been described previously [14–18]. Coding sequences of all
expression plasmids were verified by DNA sequencing.
Antibodies against TPL-2 (sc-1717 and sc-720), RelA (sc-
372-G), c-Rel (sc-71), RelB (sc-226), Bcl-2 (sc-509), CD40
(sc-9096), MKK1/2 (sc-81504), Hsp (heat-shock protein) 70 (sc-
24), Hsp90α/β (sc-7947) and actin (sc-1615) were purchased
from Santa Cruz Biotechnology. Antibodies against pThr446-PKR
(double-stranded-RNA-dependent protein kinase) (ab32036) and
PKR (ab32506) were purchased from Abcam. Antibodies against
NF-κB1 p105/p50 (#3035), pSer932-NF-κB1 p105 (#4806), Lck
(#2752), pSer221-MKK1/2 (#2338) and the Myc-tag (#2276) were
from Cell Signaling Technology. Anti-FLAG (F7425) and anti-
HA (#11867423001) antibodies were from Sigma–Aldrich and
Roche respectively. TAT-1 anti-α-tubulin antibody was provided
by Professor Keith Gull (University of Oxford, Oxford, U.K.).
ABIN-2, pSer400-TPL-2 and TPL-2 (TSP3) antibodies have been
described previously [7,19,20]. Band intensities were measured
by laser densitometry using a GS-800 densitometer (Bio-Rad
Laboratories).
Transient transfection and cell lysis
Recombinant His6- or FLAG-tagged TPL-2–ABIN-2–StrepII–
HA–p105 complex was expressed in adherent HEK-293 cells as
described previously [21]. At 48 h after transfection, cells were
lysed in 50 mM Tris/HCl (pH 7.5), 1% SDS, 150 mM NaCl,
2 mM DTT (dithiothreitol), 2 mM EDTA, 10 mM NaF, 1 mM
sodium pyrophosphate, 100 nM okadaic acid and 10 mM 2-
glycerophosphate plus CompleteTM Protease Inhibitor Cocktail
(Roche) and analysed by immunoblotting.
For expression of recombinant TPL-2 complex and FLAG–
TPL-230–397 in non-adherent HEK-293 cells, cells were pelleted
by centrifugation, and resuspended at a density of 4.0 × 106
cells/ml in standard culture medium, before addition of DNA
complexed with linear polyethyleneimine (25 kDa) at a ratio
of 3:1 (w/w) to a final concentration of 2 μg of DNA/ml
(including 0.25 μg of HA–VP35 plasmid/ml). Cell density
was adjusted to 2.0 × 106 cells/ml after 5 h and cells were
lysed after 72 h. For subsequent purification, cells were lysed
in buffer A {50 mM Tris/HCl (pH 7.5), 0.5% Igepal CA-
630, 150 mM NaCl, 10 mM imidazole, 10 mM NaF, 1 mM
sodium pyrophosphate, 10 mM 2-glycerophosphate, 0.5 mM
TCEP [tris-(2-carboxyethyl)phosphine], 10% glycerol and
protease inhibitors}. FLAG–TPL-230–397 was purified after lysis
in 50 mM Tris/HCl (pH 7.5), 1% Triton X-100, 150 mM
NaCl, 1 mM EDTA, 10 mM NaF, 1 mM sodium pyrophosphate,
10 mM 2-glycerophosphate, 2 mM DTT, 100 nM okadaic acid
and 10% glycerol, supplemented with protease inhibitors.
Protein purification and analyses
Recombinant His6–TPL-2–ABIN-2–StrepII–HA–p105 complex
was subjected to three-step affinity purification. For this,
centrifuged lysates were incubated with Ni-NTA (Ni2 + -
nitrilotriacetate)–agarose (Qiagen) for 60 min, washed in DM
wash buffer [50 mM Tris/HCl (pH 7.5), 1.8 mM decyl β-D-
maltopyranoside (DM), 150 mM NaCl, 10 mM imidazole, 10 mM
NaF, 1 mM sodium pyrophosphate, 10 mM 2-glycerophosphate,
0.5 mM TCEP and 10% glycerol supplemented with protease
inhibitors], before elution with 200 mM imidazole. After
adjusting EDTA to 1 mM, eluates were incubated with StrepTactin
Sepharose (GE Healthcare) for 60 min, washed with imidazole-
free DM wash buffer. Bound protein was eluted by the addition of
2.5 mM desthiobiotin and then loaded on to an Ni2 + -charged His-
Trap HP column (GE Healthcare), washed with 50 mM Tris/HCl
(pH 7.5), 1.8 mM DM, 150 mM NaCl, 10 mM imidazole, 0.5 mM
TCEP and 10% glycerol before elution in 200 mM imidazole.
Sample purity was quantified by measuring the IR fluorescence
of Coomassie Brilliant Blue-stained protein gels (Odyssey IR
imaging system, LI-COR Biosciences). MS analysis of purified
protein was performed as described previously [22].
Recombinant FLAG–TPL-230–397 and FLAG–TPL-2–ABIN-2–
StrepII–HA–p105 complex was purified by incubating cleared
lysates with ANTI-FLAG® M2 Affinity Gel (Sigma–Aldrich)
for 60 min, followed by extensive washing with lysis buffer and
elution with 0.2 mg/ml 3 × FLAG peptide (Sigma–Aldrich) in
DM buffer.
Gel-filtration experiments were performed using a Superose 6
10/300 GL column (GE Healthcare). For analysis of endogenous
TPL-2 complexes, BMDMs were lysed in buffer A, and 1.25 mg
of cleared lysate was loaded on to a Superose 6 10/300 GL column,
calibrated using a mixture of molecular mass marker proteins
(MWGF1000, Sigma–Aldrich).
Kinase assays
Catalytic activities of recombinant TPL-2 complex and FLAG–
TPL-230–397 towards MBP (myelin basic protein) (Sigma–Aldrich)
and GST (glutathione transferase)–MKK1 were determined
in vitro using 10 nM kinase and 3.5 or 0.1 μM substrate
respectively. Assays were performed in kinase buffer,
supplemented with 1 mM ATP with or without 10 μM C34 TPL-
2 inhibitor, in the presence (MBP) or absence (GST–MKK1)
of 0.05 μCi/μl [γ -32P]ATP for 30 min at 30 ◦C. Reactions were
stopped by boiling in SDS sample buffer and then resolved
by SDS/PAGE for subsequent analysis of MBP and GST–
MKK1 phosphorylation by autoradiography and immunoblotting
respectively.
RESULTS AND DISCUSSION
VP35-mediated enhancement of protein expression
Owing to its critical role in regulating the production of
TNF by macrophages in innate immune responses, TPL-2 has
attracted attention as a potential drug target for TNF-dependent
autoimmune diseases [23]. However, despite considerable effort
by the pharmaceutical industry [23], no TPL-2 inhibitors have yet
entered pre-clinical development. As full-length TPL-2 is largely
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Figure 1 Transient transfection of HEK-293 cells activates PKR
(A) HEK-293 cells were transiently transfected with expression plasmids encoding His6–TPL-2,
ABIN-2–StrepII and HA–p105. Protein expression levels and PKR autophosphorylation on
Thr446 were monitored by immunoblotting of cell lysates prepared 5, 24, 48 and 72 h post-
transfection (p.t.). (B) Immunoblot analysis of PKR autophosphorylation on Thr446 in lysates of
cells transiently transfected with empty control plasmid only.
insoluble when expressed alone, inhibitor screens have used a
truncated form of TPL-2 (TPL-230–397) with improved solubility
[24,25]. However, purification of TPL-230–397 from baculovirus-
infected insect cells achieves only 40% purity, with a substantial
fraction aggregated and catalytically inactive. Consequently, there
is a need for alternative strategies to produce soluble and
catalytically active TPL-2 kinase, preferably in its native full-
length conformation. In the present study, we developed a novel
method to produce substantial amounts of purified soluble full-
length TPL-2 associated with its cellular binding partners ABIN-2
and NF-κB1 p105.
The mammalian HEK-293 cell line is widely used as an
expression host for the transient expression of recombinant
proteins by transient transfection, as well as for commercial
production of recombinant therapeutics, because of its ability
to provide a close to physiological environment for exogenously
expressed mammalian proteins [26–28]. However, protein yields
are usually much lower than in most commonly used non-
mammalian expression hosts, such as Escherichia coli, yeast and
baculovirus-infected insect cells [29].
As shown previously, transfection of HEK-293 cells with DNA
plasmids activated intracellular antiviral signalling pathways that
restricted protein synthesis through activation of PKR, which
inhibits translation by phosphorylating the α-subunit of eIF2
(eukaryotic translation initiation factor 2) [15,30] (Figure 1A).
Transfection-induced PKR activation was independent of
recombinant protein expression, as empty vector had the same
effect (Figure 1B). This suggested that PKR-mediated inhibition
of translation may limit the amount of recombinant protein that
can be produced in HEK-293 cells by transient transfection.
Viruses have evolved elaborate mechanisms to subvert PKR
activation in infected cells [30]. For example, the VP35 protein
of Ebola virus binds to double-stranded RNA and antagonizes
PKR activation following viral infection [31]. Importantly, VP35
has been shown to also inhibit PKR activation in cells transiently
transfected with DNA plasmids [15]. This raised the possibility
that VP35 could be employed to boost the transient expression of
recombinant proteins in HEK-293 cells.
To test this, HEK-293 cells were transiently transfected
with plasmids encoding TPL-2, ABIN-2 and NF-κB1 p105
together with increasing amounts of an expression plasmid
encoding Ebola virus VP35 or empty vector. At 48 h after
transfection, protein expression levels and PKR activation status
were monitored by immunoblotting. Strikingly, VP35 induced a
dose-dependent increase in the levels of each of the recombinant
proteins (Figure 2A). As expected, VP35 expression substantially
decreased PKR activation (Figure 2B). Quantification of six
separate experiments demonstrated that co-transfection of VP35
plasmid induced a mean 15-fold increase in TPL-2 expression
(Figure 2C). VP35 co-expression might therefore allow the
isolation of significantly increased amounts of recombinant TPL-
2 kinase complex from transiently transfected HEK-293 cells.
Purification of recombinant TPL-2–ABIN-2–NF-κB1 p105 complex
from HEK-293 cells co-expressing VP35
It was next tested whether recombinant TPL-2–ABIN-2–
NF-κB1 p105 complex could be efficiently purified from
Figure 2 VP35 enhances protein expression of co-transfected TPL-2, ABIN-2 and NF-κB1 p105
(A) HEK-293 cells were transiently transfected with expression vectors encoding His6–TPL-2, ABIN-2–StrepII and HA–p105 (1 μg each) with or without increasing concentrations of expression
plasmid encoding HA–VP35 (0.05–0.8 μg) or were left untransfected. After 48 h of culture, cell lysates were immunoblotted. (B) HEK-293 cells were transiently transfected with expression plasmids
encoding each of the TPL-2 complex components (as in A) with or without 0.8 μg of VP35 plasmid. Protein expression levels and PKR activation were analysed by immunoblotting. (C) Laser
densitometric quantification of fold increases of His6–TPL-2 expression upon HA–VP35 co-transfection in six independent experiments performed as in (B). Results are mean +− S.D. increases
(*P = 0.01; Student’s paired t test).
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Figure 3 Affinity purification of TPL-2–ABIN-2–NF-κB1 p105 complex
HEK-293 cells were transiently transfected with expression vectors encoding His6–TPL-2, ABIN-2–StrepII and HA–p105 or empty vector together with HA–VP35 vector. After 72 h, the TPL-2 complex
was subjected to three-step affinity purification. Protein eluates were resolved by SDS/PAGE and analysed by Coomassie Brilliant Blue G-250 staining (A) or immunoblotting (B). Arrowheads in (A)
indicate the position of the most abundant proteins identified by MS analysis. (C) Purified recombinant TPL-2–ABIN-2–NF-κB1 p105 complex was resolved by gel filtration, using a Superose 6
10/300 GL column. Eluate fractions (1 ml) were immunoblotted. V0, void volume. (D) HEK-293 cells were co-transfected with vectors encoding FLAG–TPL-230–397 or with no insert, plus HA–VP35
vector. Cell lysates (72 h) were immunoprecipitated with anti-FLAG antibody and FLAG peptide-eluted proteins were resolved by SDS/PAGE, and analysed by Coomassie Brilliant Blue G-250 staining
and immunoblotting (E). (F) Purified recombinant TPL-2–ABIN-2–NF-κB1 p105 complex and FLAG-TPL-230–397 were immunoblotted. Molecular masses (kDa) of marker proteins are indicated. FL,
FLAG.
non-adherent HEK-293 cells co-expressing VP35. A three-
step affinity purification protocol was developed that involved
sequential purification of His6–TPL-2 and ABIN-2–StrepII via
their affinity tags. Analysis of eluates by SDS/PAGE and
Coomassie Brilliant Blue staining revealed three major bands
migrating at approximately 110, 60 and 50 kDa (Figure 3A), the
main constituents of which were subsequently confirmed as NF-
κB1 p105, TPL-2 and ABIN-2 respectively by MS (Table 1). MS
analysis also indicated specific co-purification of p50, RelA, c-
Rel, RelB and the molecular chaperone Hsp70, but not VP35,
with recombinant TPL-2 complex, which was confirmed by
immunoblotting (Figure 3B). The purity of isolated TPL-2–
ABIN-2–NF-κB1 p105 complex was >90%, with a yield of
over 1 mg of purified complex per litre of cultured non-adherent
HEK-293 cells.
Co-isolation of Rel proteins was probably due to specific
interaction with NF-κB1 p105, which functions as an IκB
protein [32], and was consistent with earlier reports showing
co-precipitation of Rel proteins with TPL-2 and ABIN-2
[6,7,33]. Hsps have been reported to associate with aggregated
FLAG-tagged TPL-230–397 when purified from insect cells [25].
Association of small amounts of Hsp70 with purified TPL-2–
ABIN-2–NF-κB1 p105 complex thus raised the possibility that
the recombinant complex might have been, at least partially,
aggregated. However, gel-filtration experiments indicated that
TPL-2 complexes were soluble and not aggregated. TPL-2, ABIN-
2 and NF-κB1 p105 co-eluted as one peak together with NF-κB1
p50, with an approximate molecular mass of 670 kDa, and no
complex was detected in the void volume. Furthermore, analysis
of total cell lysates of BMDMs by gel filtration demonstrated that
endogenous TPL-2, ABIN-2 and NF-κB1 p105 were also present
in complexes of approximately 670 kDa (Figure 3C), consistent
with the previously reported molecular mass of NF-κB1 p105-
containing complexes [34].
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Figure 4 Regulation of TPL-2 complex activity and phosphorylation
(A) In vitro kinase assay (KA) using purified TPL-2–ABIN-2–NF-κB1 p105 complex or FLAG–TPL-230–397 as kinases (10 nM) and MBP (3.5 μM) or GST–MKK1 (0.1 μM) as substrates. MBP
phosphorylation was assessed in the presence of 0.05 μCi/μl [γ -32P]ATP (32P) and analysed by autoradiography. Phosphorylation of GST–MKK1 on Ser221 was detected by immunoblotting. The
50 kDa band is indicated. (B) FLAG–TPL-2, ABIN-2–StrepII and HA–p105 were expressed transiently in VP35 co-transfected HEK-293 cells with or without 3 × HA–IKK-2. At 48 h after transfection,
TPL-2 complexes were immunoprecipitated (IP) with anti-FLAG antibody, and phosphorylation of TPL-2 on Ser400 and NF-κB1 p105 on Ser932 was analysed by immunoblotting. FL, FLAG.
Table 1 MS analysis of purified protein complexes
Molecular Number
Protein Gene name mass (kDa) Coverage (%) of peptides
TPL-2 complex
TPL-2 MAP3K8 53.9* 84 29
NFκB1 p105/p50 NFKB1 106.9*/49.2† 72 71
ABIN-2 TNIP2 49.8* 66 35
Hsp70 HSPA1A 70.0 61 30
RelA (p65) RELA 60.2 36 13
c-Rel REL 68.5 17 8
RelB RELB 62.1 8 3
TPL-230–397
TPL-2 MAP3K8 42.9* 70 100
Hsp90α/β HSP90AA1 85.6 57 97
HSP90AB1 83.3 56 53
Hsp70 HSPA1A 70.0 60 105
*Molecular mass of recombinant protein.
†Molecular mass calculated according to Ciechanover et al. [41].
FLAG–TPL-230–397 purified from transiently transfected HEK-
293 cells co-expressing VP35 was of low purity (∼21%) and
stoichiometrically associated with Hsp70 and Hsp90 (Figures 3D
and 3E, and Table 1). Immunoblotting revealed that significantly
more Hsp70 bound to TPL-230–397 than to the purified TPL-2–
ABIN-2–NF-κB1 p105 complex, whereas Hsp90 only detectably
associated with TPL-230–397 (Figure 3F).
Together, these findings suggest that high-level expression of
TPL-2 with its physiological binding partners NF-κB1 p105 and
ABIN-2 in HEK-293 cells generated a complex that required
minimal association with chaperone proteins. This was consistent
with genetic data showing that NF-κB1 p105 and ABIN-2 are
essential to maintain steady-state levels of TPL-2 protein [5,7–
9]. Recombinant TPL-2–ABIN-2–NF-κB1 p105 complexes could
therefore be purified efficiently from transiently transfected HEK-
293 cells that co-express VP35 in a non-aggregated soluble form.
Figure 5 VP35 enhances expression of recombinant proteins independently
of cellular localization
HEK-293 cells were transiently transfected with expression plasmids encoding Myc–His–TBK1,
Lck, CD40 or Bcl-2 with or without HA–VP35 or empty vector. At 48 h after transfection, lysates
were analysed by immunoblotting.
Activity and regulation of TPL-2–ABIN-2–NF-κB1 p105 complexes
Next, we tested whether TPL-2–ABIN-2–NF-κB1 p105 complex,
isolated from HEK-293 cells co-expressing VP35, was catalyt-
ically active. Purified TPL-2 complex readily phosphorylated a
peptide substrate corresponding to the activation loop sequence
of MKK1/2 in vitro. Negligible catalytic activity was detected
when recombinant TPL-2 complex was pre-incubated with a
highly selective TPL-2 inhibitor C34 [35] or when kinase-inactive
mutant TPL-2D270A complex was assayed (Supplementary Figure
S1 at http://www.biochemj.org/bj/452/bj4520359add.htm). The
specific activity of complexed TPL-2 was not altered by VP35
co-expression (results not shown).
Within cells, TPL-2 MKK1/2 kinase activity is inhibited
through direct interaction with NF-κB1 p105 [5,8]. However,
NF-κB1 p105 binding has no effect on the ability of TPL-2 to
phosphorylate a small protein substrate, such as MBP [20]. To
investigate whether TPL-2 was sensitive to NF-κB1 p105 inhibi-
tion when co-expressed with VP35, the specific activity of purified
TPL-2 complex was compared with that of purified FLAG–TPL-
230–397, using GST–MKK1 and MBP as substrates. Although
both enzyme preparations exhibited similar activity towards
MBP, only FLAG–TPL-230–397 phosphorylated GST–MKK1
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on Ser221 (Figure 4A), indicating that NF-κB1 p105 regulation
of TPL-2 within the purified complex was intact.
In cells, agonist activation of TPL-2 MKK1/2 kinase activity
is directly regulated by IKK-2 through phosphorylation of NF-
κB1 p105 on Ser927 and Ser932, which triggers NF-κB1 p105
proteasomal degradation, and direct phosphorylation of TPL-
2 on Ser400 in its C-terminus [8,10,20,22]. Co-expression of
IKK-2 with TPL-2, ABIN-2 and NF-κB1 p105 strongly induced
phosphorylation of Ser932 in NF-κB1 p105 and Ser400 in TPL-2
(Figure 4B). The VP35 methodology therefore allows generation
of substantial amounts of TPL-2 complex that is phosphorylated
on physiological regulatory sites, which could then be used for
in vitro functional studies.
VP35 co-expression increases expression of other recombinant
proteins
To investigate whether VP35 co-expression might be used
generally to boost protein production by HEK-293 cells, cells
were transfected with expression constructs encoding TBK1,
Lck, CD40 and Bcl-2 individually with or without VP35.
Protein levels were then analysed by immunoblotting. VP35
induced substantial increases in expression of each recombinant
protein (Figure 5), similar to that observed with TPL-2, ABIN-
2 and NF-κB1 p105. Importantly, enhancement of expression
appeared to be independent of cellular localization, since,
in addition to cytoplasmic TBK1, expression of transiently
expressed membrane-associated (Lck), transmembrane (CD40)
and mitochondrial (Bcl-2) proteins was increased.
Conclusions
HEK-293 cells are commonly used for expression of recombinant
proteins because of their efficient transient transfection and
ability to grow in suspension cultures [27,28,36–39]. However,
achievable yields in HEK-293 cells are far lower than possible
with E. coli and baculovirus expression systems [29]. The
activation of PKR by transfected DNA plasmids decreases
translation and limits recombinant protein production by HEK-
293 cells [40]. By blocking activation of PKR, we have shown
that Ebola virus VP35 substantially increased the yield of
co-expressed recombinant proteins. This simple approach has
potentially broad implications for structural studies and drug
screening, which require large amounts of purified recombinant
protein.
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Figure S1 MKK1/2 peptide phosphorylation by purified TPL-2–ABIN-2–NF-
κB1 p105 complexes
(A) In vitro kinase assay using purified wild-type (WT) TPL-2 or kinase-inactive
TPL-2D270A (D270A) complexes (30 nM kinase) and 50 μM MKK1/2 peptide
(YAGQLIDSMANSFVGTAGKK-biotin) as substrate. Assays were performed in kinase buffer
[50 mM Tris/HCl (pH 7.0), 0.03 % Brij-35, 2 mM DTT, 5 mM 2-glycerophosphate, 5 mM MnCl2
and 5 % DMSO], supplemented with 0.1.mM ATP and 0.02 μCi/μl [γ -32P]ATP, for 60 min at
30◦C. Reactions were stopped by the addition of EDTA, and ultrafiltrates (10 kDa) were spotted
on to streptavidin-coated membranes (SAM2, Promega). Membranes were extensively washed
in TBS (Tris-buffered saline)/1 % SDS, 2 M NaCl and 2 M NaCl/1 % H3PO4 before quantification
of peptide phosphorylation by phosphorimaging. Results are means+−S.D. (B) In vitro kinase
assay of affinity-purified wild-type TPL-2 complex performed as in (A) with or without C34
TPL-2 inhibitor.
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